ImmunoGen, Inc. (NASDAQ:IMGN) Files An 8-K Results of Operations and Financial Condition

ImmunoGen, Inc. (NASDAQ:IMGN) Files An 8-K Results of Operations and Financial Condition
ITEM 2.02 RESULTS OF OPERATION AND FINANCIAL CONDITION

Story continues below

On May 3, 2019, ImmunoGen, Inc. (Nasdaq: IMGN) issued a press release to announce the companys financial results for the quarter ended March 31, 2019.The press release announcing financial results for the quarter ended March 31, 2019 is included as Exhibit 99.1 and incorporated herein by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

(d): The following exhibit is being furnished herewith:

IMMUNOGEN INC Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 imgn_Current_folio_8K_Ex_99_1 Exhibit 99.1 ImmunoGen Reports Recent Progress and First Quarter 2019 Financial Results   Encouraging Efficacy Signal Observed in Pre-Specified Subset of Patients in Phase 3 FORWARD I Study; Company to Meet with Regulators this Quarter to Discuss Potential Path Forward for Mirvetuximab Soravtansine Monotherapy   FORWARD II Trial with Mirvetuximab Combinations Continues to Enroll,…
To view the full exhibit click here

About ImmunoGen, Inc. (NASDAQ:IMGN)

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.

An ad to help with our costs